Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …

PURPOSE Since the 1980s, both the incidence of differentiated thyroid cancer (DTC) and
use of radioactive iodine (RAI) treatment increased markedly. RAI has been associated with …

Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the
patients treated since then are probably numbered in the millions. Fifty to 90% of …

Radiopharmaceutical therapies are gaining increasing prominence as they improve survival
in patients with common diseases such as metastatic prostate cancer (1, 2). However …

Importance The incidence of detected thyroid cancer cases has been increasing in the
United States since 1975. The majority of thyroid cancers are differentiated cancers with …

Use of radioactive iodine is an essential adjuvant treatment strategy after thyroidectomy in
patients with differentiated thyroid carcinoma. Although generally safe, radioiodine therapy …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Background Treatment of differentiated thyroid carcinoma (DTC) often involves
administration of radioactive iodine (I-131) for remnant ablation or adjuvant therapy. As DTC …

Background: The potential risk of subsequent malignant neoplasms (SMNs) after radioactive
iodine (RAI) treatment of thyroid cancer (TC) is an important concern. Methods: A systematic …